March 8 – 9, 2012 Korea Investor Conference

Shilla Hotel Seoul, Korea The 6th annual Citi Korea Investor Conference has evolved into one of the premier corporate access […]

Read more »

Grant Thornton to Sponsor a Workshop on Funding Strategies for Life Sciences Companies

Research indicates that the financial crisis has led to a shift in the popularity, focus, and types of deals that are being done.

Read more »

February 27-28 2012 Star Ratings Symposium

Star Ratings Symposium February 27-28 2012 Crowne Plaza Anaheim Resort, Anaheim, CA   How would your rank your strategy for […]

Read more »

LoneStar Heart is Focused on Preserving & Restoring Heart Functions to Heart Failure Patients

Congestive heart failure affects as many as 5 million Americans and with an aging population, more than half a million patients are diagnosed with the condition each year.

Read more »

CorInnova is Developing Technologies to Restore Heart Function for Heart Failure Patients

CorInnova is currently trialing a cardiac compression device known as CorAmend that can be implanted and explanted without ever contacting the patient’s blood

Read more »

Castlewood Surgical – Improving Coronary Bypass Grafting with “No Metal” Surgical Assistance

The Cyclone System allows a surgeon to eliminate the aortic side-biting clamp traditionally used in coronary artery bypass grafting (CABG).

Read more »

Editor’s Note December 27, 2012

With a new year upon us, we are reminded of the year that is now coming to a close.  2011 […]

Read more »

A New Era In Medical Devices Provides Critical Information in Real Time

The internet has ushered in a new era in Medical Devices as they begin to provide connectivity and communications to the health system to monitor the patient and provide critical clinical information.

Read more »

Thermalin Diabetes Follows the “Coulter Process” And Addresses Significant Needs in the Insulin Market

Thermalin’s therapeutic proteins will address medical needs related to diabetes and its complications.

Read more »

Anavex Life Sciences Challenges the Basic Assumptions In Treating Alzheimer’s Disease

The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose clinical trial.

Read more »